NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

液體活檢全球市場預測:2021-2028

Global Liquid Biopsy Market Forecast 2021-2028

出版商 Inkwood Research 商品編碼 995692
出版日期 內容資訊 英文 270 Pages
商品交期: 2-3個工作天內
價格
液體活檢全球市場預測:2021-2028 Global Liquid Biopsy Market Forecast 2021-2028
出版日期: 2021年03月15日內容資訊: 英文 270 Pages
簡介

在預測期內2021-2028年,全球液體活檢市場預計將以18.91%的複合年增長率增長。市場上老年人的癌症患病率增加,消費者對診斷中心的需求不斷變化,無創液體活檢,組織/腫瘤不可知藥物的出現以及患者對液體活檢測試的偏愛,這是促進癌症發展的一個因素。 。

本報告調查了液體活檢的全球市場,並概述了市場,對影響市場的因素進行了分析,每個細分市場,細分市場和地區的市場預測以及主要公司的概況。

目錄

第1章調查範圍/調查方法

  • 調查目的
  • 調查範圍
  • 調查方法
  • 先決條件/限制

第2章執行摘要

  • 市場規模/估計
  • 市場概況

第3章市場動態

  • 市場定義
  • 主要驅動因素
    • 增加政府舉措
    • 老年人癌症病例的發病率
    • 消費者對診斷中心需求的變化
    • 液體活檢測試的非侵入性
    • 組織/非腫瘤藥物的出現
    • 患者偏愛液體活檢
    • 技術進步
  • 主要製約因素
    • 對標準操作程序(SOPS)缺乏共識
    • 獎勵結構不足
    • 高昂的測試成本
    • 兌換問題
    • 缺乏熟練的專業人員

第4章主要分析

  • 波特的五種力量分析
  • COVID-19對液體活檢市場的影響
  • 液體活檢的主要舉措
  • 監管框架
  • 市場機會矩陣
  • 供應商狀況
  • 主要投資見解

第5章市場:通過治療用途

  • 肺癌
  • 乳腺癌
  • 前列腺癌
  • 大腸癌
  • 黑色素瘤
  • 其他類型的癌症
  • 非腫瘤學應用

第6章市場:通過臨床應用

  • 治療監測
  • 預後/復發監測
  • 治療選擇
  • 診斷與篩查

第7章市場:按生物標記物類型

  • 核酸
  • 蛋白
  • 細胞外囊泡
  • 個單元

第8章市場:通過分析平台

  • NGS
  • 芯片
  • PCR
  • 蛋白質組學
  • 其他分析平台

第9章市場:按分析目的

  • 早期發現/篩查
  • 治療指導
  • 監控
  • 診斷

第10章市場:按產品

  • 循環腫瘤DNA(CTDNA)
  • 循環腫瘤細胞(CTCS)
  • 無細胞DNA(CFDNA)
  • 細胞外囊泡及其他

第11章市場:按最終用戶

  • 診所實驗室
  • 醫院
  • 臨床診斷實驗室

第12章區域分析

  • 北美
    • 市場規模/估計
    • 主要增長推動力
    • 主要問題
    • 主要公司
    • 國家分析
  • 歐洲
  • 亞太地區
  • 其他地區

第13章競爭情況

  • 主要戰略發展
    • 併購
    • 產品發佈和開發
    • 夥伴關係,合同/合同與合作
    • 業務擴展/批准/公告
  • 公司簡介
    • ADAPTIVE BIOTECHNOLOGIES
    • AGILENT TECHNOLOGIES INC
    • ANGLE PLC
    • BECTON, DICKINSON AND COMPANY (BD)
    • BIOCEPT INC
    • BIO-RAD LABORATORIES INC
    • F. HOFFMANN-LA ROCHE
    • FOUNDATION MEDICINE
    • GRAIL
    • GUARDANT HEALTH INC
    • ILLUMINA INC
    • MDXHEALTH SA
    • MENARINI-SILICON BIOSYSTEMS
    • MYRIAD GENETICS INC
    • NATERA
    • PERSONAL GENOME DIAGNOSTICS
    • QIAGEN NV
    • THERMO FISHER SCIENTIFIC INC
目錄
Product Code: 16840

KEY FINDINGS

The global liquid biopsy market is projected to grow with a CAGR of 18.91%, over the forecasted years of 2021 to 2028. The increasing prevalence of cancer in the older populace, the shifting consumer demand for diagnostic centers, the non-invasive nature of liquid biopsy testing, the emergence of tissue/tumor-agnostic drugs, and patients' preference for liquid biopsy testing, are among the chief forces driving the market growth.

MARKET INSIGHTS

A liquid biopsy entails a non-invasive method, that helps monitor and determine cancer and other diseases. In order to perform a liquid biopsy, blood or other fluids, including, urine is collected, sequenced, and analyzed by the use of next-generation sequencing (NGS) systems and assays. Tissue biopsy, an invasive procedure, is now being replaced by liquid biopsy, owing to the latter's efficiency.

Continually transitioning consumer demands have generated a shift in diagnostic testing, from commercial laboratories and hospitals, closer to the patients' home. As a result, the change has considerably minimized the overall cost of testing. The majority of healthcare services being delivered at homes, across several countries, are mainly for urban areas, with a reduced focus on rural areas. However, developing countries have a high proportion of people living in rural areas with few diagnostic centers, and low accessibility. Such regions also observe a high rate of cancer deaths, accredited to the lack of disease awareness, thereby leading to the ignorance of treatment and diagnosis.

REGIONAL INSIGHTS

The global liquid biopsy market growth is assessed through the evaluation of North America, Europe, the Asia-Pacific, and the rest of the world. The Asia-Pacific is set to be the leading region over the forecast period, owing to factors such as, the increasing need for liquid biopsy products, the surging incidence of cancer, mainly due to low awareness and delayed detection, and the initiatives undertaken by the government.

COMPETITIVE INSIGHTS

Since the global liquid biopsy market is still developing and emerging, customers often prefer trying popular products, as it is convenient to switch from one product to another. However, with this aspect, the customers' loyalty is jeopardized. Hence, industrial rivalry is considered to be medium to high.

Some of the leading companies operating in the market are: Becton, Dickinson, and Company (BD), Agilent Technologies Inc, Qiagen NV, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. MARKET DEFINITION
  • 3.2. KEY DRIVERS
    • 3.2.1. RISING GOVERNMENT INITIATIVES
    • 3.2.2. INCIDENCE OF CANCER CASES IN OLDER POPULACE
    • 3.2.3. SHIFTING DEMAND OF CONSUMERS FOR DIAGNOSTIC CENTERS
    • 3.2.4. NON-INVASIVE NATURE OF LIQUID BIOPSY TESTING
    • 3.2.5. EMERGENCE OF TISSUE/TUMOR-AGNOSTIC DRUGS
    • 3.2.6. PATIENTS' PREFERENCE FOR LIQUID BIOPSY TESTING
    • 3.2.7. TECHNOLOGICAL ADVANCEMENTS
  • 3.3. KEY RESTRAINTS
    • 3.3.1. LACK OF CONSENSUS ON STANDARD OPERATING PROCEDURES (SOPS)
    • 3.3.2. POOR COMPENSATION STRUCTURES
    • 3.3.3. HIGH COST OF THE TEST
    • 3.3.4. REIMBURSEMENT ISSUES
    • 3.3.5. DEARTH OF SKILLED PROFESSIONALS

4. KEY ANALYTICS

  • 4.1. PORTER'S FIVE FORCES ANALYSIS
    • 4.1.1. THREAT OF NEW ENTRIES
    • 4.1.2. THREAT OF SUBSTITUTIONS
    • 4.1.3. BUYERS POWER
    • 4.1.4. SUPPLIERS POWER
    • 4.1.5. COMPETITIVE RIVALRY
  • 4.2. IMPACT OF COVID-19 ON LIQUID BIOPSY MARKET
  • 4.3. KEY LIQUID BIOPSY INITIATIVES
  • 4.4. REGULATORY FRAMEWORK
  • 4.5. OPPORTUNITY MATRIX
  • 4.6. VENDOR LANDSCAPE
  • 4.7. KEY INVESTMENT INSIGHTS

5. MARKET BY THERAPEUTIC APPLICATION

  • 5.1. LUNG CANCER
  • 5.2. BREAST CANCER
  • 5.3. PROSTATE CANCER
  • 5.4. COLORECTAL CANCER
  • 5.5. MELANOMA CANCER
  • 5.6. OTHER TYPES OF CANCER
  • 5.7. NON-ONCOLOGY APPLICATION

6. MARKET BY CLINICAL APPLICATION

  • 6.1. TREATMENT MONITORING
  • 6.2. PROGNOSIS AND REOCCURRENCE MONITORING
  • 6.3. TREATMENT SELECTION
  • 6.4. DIAGNOSIS AND SCREENING

7. MARKET BY BIOMARKER TYPE

  • 7.1. NUCLEIC ACID
  • 7.2. PROTEIN
  • 7.3. EXTRACELLULAR VESICLES
  • 7.4. CELLS

8. MARKET BY ANALYSIS PLATFORM

  • 8.1. NGS
  • 8.2. MICROARRAY
  • 8.3. PCR
  • 8.4. PROTEOMICS
  • 8.5. OTHER ANALYSIS PLATFORMS

9. MARKET BY ANALYSIS PURPOSE

  • 9.1. EARLY DETECTION/SCREENING
  • 9.2. THERAPY GUIDANCE
  • 9.3. MONITORING
  • 9.4. DIAGNOSIS

10. MARKET BY PRODUCT

  • 10.1. CIRCULATING TUMOR DNA (CTDNA)
  • 10.2. CIRCULATING TUMOR CELLS (CTCS)
  • 10.3. CELL-FREE DNA (CFDNA)
  • 10.4. EXTRACELLULAR VESICLES AND OTHERS

11. MARKET BY END-USER

  • 11.1. PHYSICIANS' OFFICE LABORATORIES
  • 11.2. HOSPITALS
  • 11.3. CLINICAL DIAGNOSTIC LABORATORIES

12. GEOGRAPHICAL ANALYSIS

  • 12.1. NORTH AMERICA
    • 12.1.1. MARKET SIZE & ESTIMATES
    • 12.1.2. KEY GROWTH ENABLERS
    • 12.1.3. KEY CHALLENGES
    • 12.1.4. KEY PLAYERS
    • 12.1.5. COUNTRY ANALYSIS
      • 12.1.5.1. UNITED STATES
      • 12.1.5.2. CANADA
  • 12.2. EUROPE
    • 12.2.1. MARKET SIZE & ESTIMATES
    • 12.2.2. KEY GROWTH ENABLERS
    • 12.2.3. KEY CHALLENGES
    • 12.2.4. KEY PLAYERS
    • 12.2.5. COUNTRY ANALYSIS
      • 12.2.5.1. UNITED KINGDOM
      • 12.2.5.2. FRANCE
      • 12.2.5.3. GERMANY
      • 12.2.5.4. ITALY
      • 12.2.5.5. RUSSIA
      • 12.2.5.6. BELGIUM
      • 12.2.5.7. POLAND
      • 12.2.5.8. REST OF EUROPE
  • 12.3. ASIA-PACIFIC
    • 12.3.1. MARKET SIZE & ESTIMATES
    • 12.3.2. KEY GROWTH ENABLERS
    • 12.3.3. KEY CHALLENGES
    • 12.3.4. KEY PLAYERS
    • 12.3.5. COUNTRY ANALYSIS
      • 12.3.5.1. JAPAN
      • 12.3.5.2. CHINA
      • 12.3.5.3. INDIA
      • 12.3.5.4. SOUTH KOREA
      • 12.3.5.5. AUSTRALIA & NEW ZEALAND
      • 12.3.5.6. THAILAND
      • 12.3.5.7. INDONESIA
      • 12.3.5.8. VIETNAM
      • 12.3.5.9. REST OF ASIA-PACIFIC
  • 12.4. REST OF WORLD
    • 12.4.1. MARKET SIZE & ESTIMATES
    • 12.4.2. KEY GROWTH ENABLERS
    • 12.4.3. KEY CHALLENGES
    • 12.4.4. KEY PLAYERS
    • 12.4.5. REGIONAL ANALYSIS
      • 12.4.5.1. LATIN AMERICA
      • 12.4.5.2. MIDDLE EAST & AFRICA

13. COMPETITIVE LANDSCAPE

  • 13.1. KEY STRATEGIC DEVELOPMENTS
    • 13.1.1. MERGERS & ACQUISITIONS
    • 13.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
    • 13.1.3. PARTNERSHIPS, CONTRACTS/AGREEMENTS & COLLABORATIONS
    • 13.1.4. BUSINESS EXPANSIONS/ APPROVALS/ ANNOUNCEMENTS
  • 13.2. COMPANY PROFILES
    • 13.2.1. ADAPTIVE BIOTECHNOLOGIES
    • 13.2.2. AGILENT TECHNOLOGIES INC
    • 13.2.3. ANGLE PLC
    • 13.2.4. BECTON, DICKINSON AND COMPANY (BD)
    • 13.2.5. BIOCEPT INC
    • 13.2.6. BIO-RAD LABORATORIES INC
    • 13.2.7. F. HOFFMANN-LA ROCHE
    • 13.2.8. FOUNDATION MEDICINE
    • 13.2.9. GRAIL
    • 13.2.10. GUARDANT HEALTH INC
    • 13.2.11. ILLUMINA INC
    • 13.2.12. MDXHEALTH SA
    • 13.2.13. MENARINI-SILICON BIOSYSTEMS
    • 13.2.14. MYRIAD GENETICS INC
    • 13.2.15. NATERA
    • 13.2.16. PERSONAL GENOME DIAGNOSTICS
    • 13.2.17. QIAGEN NV
    • 13.2.18. THERMO FISHER SCIENTIFIC INC

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - LIQUID BIOPSY
  • TABLE 2: GOVERNMENT INITIATIVES FOR CANCER AND LIQUID BIOPSY TESTING IN SOME COUNTRIES
  • TABLE 3: GLOBAL LIQUID BIOPSY MARKET, BY THERAPEUTIC APPLICATION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 4: GLOBAL LIQUID BIOPSY MARKET, BY THERAPEUTIC APPLICATION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 5: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 6: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 7: GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 8: GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 9: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PLATFORM, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 10: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PLATFORM, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 11: NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES
  • TABLE 12: ADVANTAGES OF DROPLET DIGITAL PCR FOR SINGLE-CELL ANALYSIS
  • TABLE 13: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PURPOSE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 14: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PURPOSE, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 15: GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 16: GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 17: GLOBAL LIQUID BIOPSY MARKET, BY END-USER, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 18: GLOBAL LIQUID BIOPSY MARKET, BY END-USER, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 19: GLOBAL LIQUID BIOPSY MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 20: GLOBAL LIQUID BIOPSY MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 21: NORTH AMERICA LIQUID BIOPSY MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 22: NORTH AMERICA LIQUID BIOPSY MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 23: LEADING PLAYERS OPERATING IN NORTH AMERICA LIQUID BIOPSY MARKET
  • TABLE 24: EUROPE LIQUID BIOPSY MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 25: EUROPE LIQUID BIOPSY MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 26: LEADING PLAYERS OPERATING IN EUROPE LIQUID BIOPSY MARKET
  • TABLE 27: ASIA-PACIFIC LIQUID BIOPSY MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 28: ASIA-PACIFIC LIQUID BIOPSY MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 29: LEADING PLAYERS OPERATING IN ASIA-PACIFIC LIQUID BIOPSY MARKET
  • TABLE 30: REST OF WORLD LIQUID BIOPSY MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 31: REST OF WORLD LIQUID BIOPSY MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 32: LEADING PLAYERS OPERATING IN ASIA-PACIFIC LIQUID BIOPSY MARKET
  • TABLE 33: LIST OF MERGERS & ACQUISITIONS
  • TABLE 34: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
  • TABLE 35: LIST OF PARTNERSHIPS AND AGREEMENTS
  • TABLE 36: LIST OF BUSINESS EXPANSIONS AND DIVESTITURES

LIST OF FIGURES

  • FIGURE 1: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 2: OPPORTUNITY MATRIX
  • FIGURE 3: VENDOR LANDSCAPE
  • FIGURE 4: KEY INVESTMENT INSIGHTS
  • FIGURE 5: GLOBAL LIQUID BIOPSY MARKET, BY THERAPEUTIC APPLICATION, IN 2020
  • FIGURE 6: GLOBAL LIQUID BIOPSY MARKET, BY LUNG CANCER, 2021-2028 (IN $ MILLION)
  • FIGURE 7: GLOBAL LIQUID BIOPSY MARKET, BY BREAST CANCER, 2021-2028 (IN $ MILLION)
  • FIGURE 8: GLOBAL LIQUID BIOPSY MARKET, BY PROSTATE CANCER, 2021-2028 (IN $ MILLION)
  • FIGURE 9: GLOBAL LIQUID BIOPSY MARKET, BY COLORECTAL CANCER, 2021-2028 (IN $ MILLION)
  • FIGURE 10: GLOBAL LIQUID BIOPSY MARKET, BY MELANOMA CANCER, 2021-2028 (IN $ MILLION)
  • FIGURE 11: GLOBAL LIQUID BIOPSY MARKET, BY OTHER TYPES OF CANCER, 2021-2028 (IN $ MILLION)
  • FIGURE 12: GLOBAL LIQUID BIOPSY MARKET, BY NON-ONCOLOGY APPLICATION, 2021-2028 (IN $ MILLION)
  • FIGURE 13: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, IN 2020
  • FIGURE 14: GLOBAL LIQUID BIOPSY MARKET, BY TREATMENT MONITORING, 2021-2028 (IN $ MILLION)
  • FIGURE 15: GLOBAL LIQUID BIOPSY MARKET, BY PROGNOSIS AND REOCCURRENCE MONITORING, 2021-2028 (IN $ MILLION)
  • FIGURE 16: GLOBAL LIQUID BIOPSY MARKET, BY TREATMENT SELECTION, 2021-2028 (IN $ MILLION)
  • FIGURE 17: GLOBAL LIQUID BIOPSY MARKET, BY DIAGNOSIS AND SCREENING, 2021-2028 (IN $ MILLION)
  • FIGURE 18: GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, IN 2020
  • FIGURE 19: GLOBAL LIQUID BIOPSY MARKET, BY NUCLEIC ACID, 2021-2028 (IN $ MILLION)
  • FIGURE 20: GLOBAL LIQUID BIOPSY MARKET, BY PROTEIN, 2021-2028 (IN $ MILLION)
  • FIGURE 21: GLOBAL LIQUID BIOPSY MARKET, BY EXTRACELLULAR VESICLES, 2021-2028 (IN $ MILLION)
  • FIGURE 22: GLOBAL LIQUID BIOPSY MARKET, BY CELLS, 2021-2028 (IN $ MILLION)
  • FIGURE 23: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PLATFORM, IN 2020
  • FIGURE 24: GLOBAL LIQUID BIOPSY MARKET, BY NGS, 2021-2028 (IN $ MILLION)
  • FIGURE 25: GLOBAL LIQUID BIOPSY MARKET, BY MICROARRAY, 2021-2028 (IN $ MILLION)
  • FIGURE 26: GLOBAL LIQUID BIOPSY MARKET, BY PCR, 2021-2028 (IN $ MILLION)
  • FIGURE 27: GLOBAL LIQUID BIOPSY MARKET, BY PROTEOMICS, 2021-2028 (IN $ MILLION)
  • FIGURE 28: GLOBAL LIQUID BIOPSY MARKET, BY OTHER ANALYSIS PLATFORMS, 2021-2028 (IN $ MILLION)
  • FIGURE 29: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PURPOSE, IN 2020
  • FIGURE 30: GLOBAL LIQUID BIOPSY MARKET, BY EARLY DETECTION/SCREENING, 2021-2028 (IN $ MILLION)
  • FIGURE 31: GLOBAL LIQUID BIOPSY MARKET, BY THERAPY GUIDANCE, 2021-2028 (IN $ MILLION)
  • FIGURE 32: GLOBAL LIQUID BIOPSY MARKET, BY MONITORING, 2021-2028 (IN $ MILLION)
  • FIGURE 33: GLOBAL LIQUID BIOPSY MARKET, BY DIAGNOSIS, 2021-2028 (IN $ MILLION)
  • FIGURE 34: GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT, IN 2020
  • FIGURE 35: GLOBAL LIQUID BIOPSY MARKET, BY CIRCULATING TUMOR DNA (CTDNA), 2021-2028 (IN $ MILLION)
  • FIGURE 36: GLOBAL LIQUID BIOPSY MARKET, BY CIRCULATING TUMOR CELLS (CTCS), 2021-2028 (IN $ MILLION)
  • FIGURE 37: GLOBAL LIQUID BIOPSY MARKET, BY CELL-FREE DNA (CFDNA), 2021-2028 (IN $ MILLION)
  • FIGURE 38: GLOBAL LIQUID BIOPSY MARKET, BY EXTRACELLULAR VESICLES AND OTHERS, 2021-2028 (IN $ MILLION)
  • FIGURE 39: GLOBAL LIQUID BIOPSY MARKET, BY END-USER, IN 2020
  • FIGURE 40: GLOBAL LIQUID BIOPSY MARKET, BY PHYSICIANS' OFFICE LABORATORIES, 2021-2028 (IN $ MILLION)
  • FIGURE 41: GLOBAL LIQUID BIOPSY MARKET, BY HOSPITALS, 2021-2028 (IN $ MILLION)
  • FIGURE 42: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL DIAGNOSTIC LABORATORIES, 2021-2028 (IN $ MILLION)
  • FIGURE 43: NORTH AMERICA LIQUID BIOPSY MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 44: UNITED STATES LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 45: CANADA LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 46: EUROPE LIQUID BIOPSY MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 47: UNITED KINGDOM LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 48: FRANCE LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 49: GERMANY LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 50: ITALY LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 51: RUSSIA LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 52: BELGIUM LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 53: POLAND LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 54: REST OF EUROPE LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 55: ASIA-PACIFIC LIQUID BIOPSY MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 56: JAPAN LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 57: CHINA LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 58: INDIA LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 59: SOUTH KOREA LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 60: AUSTRALIA & NEW ZEALAND LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 61: THAILAND LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 62: INDONESIA LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 63: VIETNAM LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 64: REST OF ASIA-PACIFIC LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 65: REST OF WORLD LIQUID BIOPSY MARKET, REGIONAL OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 66: LATIN AMERICA LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 67: MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)